Biomarkers in Heart Failure: Apelin Level Is not Associated With Presence and Severity of the Disease

• DOI: 10.18565/cardio.2015.2.37-41
• Publication Date: 2015-10-14T09:43:34Z
• Authors: S.V. Lakomkin Lak...; S.N. Tereshchenko...; A.V. Sychev Sychev; V.P. Masenko Masenko; G.A. Tkachev G; О.N. Gerasimova G...; E.Y. Sigalovich S...; E.N. Dankovtseva ...; D.A. Zateyshchiko...
• Keywords: Apelin; Ischemic Cardiomyopathy

We tested possibility of the use apelin-12 as a biomarker chronic heart failure (CHF). The study comprised 108 patients with I-IV functional class CHF various etiology (ischemic disease, dilation cardiomyopathy) and 40 healthy volunteers. Blood samples were taken at hospital admission before prescription pharmacological therapy. In all we carried out echocardiography calculation end-diastolic end-systolic volumes (EDV, ESV) ejection fraction (EF). plasma concentration was compared market NT-proBNP. Mean concentrations 0.86 ± 0.22 hg/ml in volunteers 0.8±0.35, 0.81 0.29, 0.68 0.38, 0.82 0.35 classes I, III, IV, respectively. There no significant differences between appelin-12 CHF. No correlations found EF, EDV, ESV, sex, age, smoking, body mass index, NT-proBNP level. Concentration NT pro-BNP level correlated severity. Thus did not show itself reliable